INTRODUCTION

Liver fibrosis is a consequence of the wound-healing response to repeated liver injury characterized by excessive deposition of extracellular matrix (ECM) molecules. There are various common causes of liver fibrosis, including hepatitis virus infection, alcoholic liver disease (ALD) or non-alcoholic steatohepatitis (NASH), which may progress to liver cirrhosis and provide a pathological basis for the development of hepatocellular carcinoma (HCC). The activation and proliferation of hepatic stellate cells (HSCs) induced by liver injury or micro-environmental stimulation lead to the synthesis and secretion of a large number of ECM molecules and exert an important role in liver fibrogenesis. Given the important role of HSCs in liver fibrogenesis, a full review of the underlying molecular mechanisms is critical to determine new diagnostic and therapeutic targets for liver fibrosis. PLK1 is overexpressed in many human tumour cells and has become a popular drug target in tumour therapy. Therefore, further study of the function of PLK1 in the cell cycle is valid. In the present study, we found that PLK1 expression was elevated in primary HSCs isolated from CCl4-induced liver fibrosis mice and LX-2 cells stimulated with TGF-β1. Knockdown of PLK1 inhibited α-SMA and Col1α1 expression and reduced the activation of HSCs in CCl4-induced liver fibrosis mice and LX-2 cells stimulated with TGF-β1. We further showed that inhibiting the expression of PLK1 reduced the proliferation of HSCs and promoted HSCs apoptosis in vivo and in vitro. Furthermore, we found that the Wnt/β-catenin signalling pathway may be essential for PLK1-mediated HSCs activation. Together, blocking PLK1 effectively suppressed liver fibrosis by inhibiting HSC activation, which may provide a new treatment strategy for liver fibrosis.

KEYWORDS
activation, HSCs, liver fibrosis, PLK1
important for normal liver development. Studies have confirmed that this pathway is closely related to the formation of HSCs and liver fibrosis. However, the mechanisms involved in the activation of HSCs by the Wnt/β-catenin pathway to participate in liver fibrosis remain unclear.

PLK1 (polo-like kinase 1) belongs to the polo-like kinase family and regulates cell mitosis, cytokinesis and DNA damage response. Importantly, previous studies have identified that PLK1 is highly expressed in a variety of cancers including HCC, pancreatic carcinoma and renal cell carcinoma, and it is associated with decreased survival in cancer patients. Several studies have shown that PLK1 is involved in the invasion and metastasis of cancer. Furthermore, blocking the expression of PLK1 can effectively inhibit the proliferation of tumour cells and induce their apoptosis. In addition, PLK1 has been demonstrated as a marker associated with the cell cycle in acute idiopathic pulmonary fibrosis (IPF) and is a therapeutic target. Considering the above findings, we speculated whether PLK1 can regulate the proliferation and apoptosis of HSCs to promote the resolution of liver fibrosis. Interestingly, a previous study identified that PLK1 phosphorylation of axin2 facilitated the GSK3-dependent phosphorylation of β-catenin by enhancing binding between GSK3 and β-catenin, offering a novel PLK1-Wnt/β-catenin signalling axis to treat prostate cancer. In our study, we investigated whether PLK1 regulates HSCs via the Wnt/β-catenin signalling pathway to influence the development of liver fibrosis.

To the best of our knowledge, this is the first study to demonstrate the essential role of PLK1 in the pathogenesis of liver fibrosis and identify the potential mechanisms involved. We found that reduced PLK1 expression effectively prevented HSC activation. In addition, we revealed that inhibition of PLK1 promoted HSC apoptosis and reduced liver fibrosis via the Wnt/β-catenin signalling pathway in vivo and in vitro.

2 | MATERIALS AND METHODS

2.1 | Mouse model of liver fibrosis

All experiments were conducted as required of the Ethics Committee and Animal Experimental Committee at Anhui Medical University. Male C57BL/6J mice (8 weeks of age) were purchased from the Animal Experiment Center of Anhui Medical University. C57BL/6J mice were intraperitoneally injected twice a week with a 10% solution of CCl4 in olive oil or olive oil alone (vehicle control) at a dose of 0.001 mL/g for 6 weeks. Mice were killed 3 days after the last injection.

2.2 | Adeno-associated virus (AAV) infection

Purified adeno-associated viral vector serotype 8 (AAV8) encoding PLK1 was generated by Hanheng Biotechnology (Shanghai, China). C57BL/6J mice received a single tail vein injection of AAV8 encoding PLK1 at a concentration of 1 × 10¹² vg/mL. The transfection efficiency was measured by Western blotting and real-time PCR analysis.

2.3 | Human samples

Ten normal and fourteen human liver fibrosis samples were received from the First Affiliated Hospital of Anhui Medical University (Anhui, China). All specimens were obtained after receiving informed consent from each patient, and the experiment was performed in accordance with the Declaration of Helsinki and with approval by the Ethics Committee of Anhui Medical University. Part of each sample was fixed in 4% paraformaldehyde and embedded in paraffin, whereas the rest was stored at −80°C.

2.4 | Isolation of primary HSCs

HSCs were isolated as previously described with some modifications. Briefly, mouse primary HSCs were isolated employing a two-step collagenase (Sigma)-pronase (Sigma) perfusion of mouse livers, followed by OptiPrep density gradient centrifugation (Axis Shield, Norway). Finally, the expression level of α-SMA (an HSC marker) was detected by Western blotting and real-time PCR.

2.5 | Histology and immunohistochemistry

A after 4% paraformaldehyde fixation and paraffin embedding, liver tissues were sectioned at 8 µm thickness for haematoxylin and eosin staining (H&E), Sirius red staining and immunohistochemical staining of α-SMA (1:400; Abcam, USA) and PLK1 (1:400; Abcam, USA) to examine liver pathology. We employed a microwave-based antigen retrieval technique following standard methods. These sections were examined by a digital slide scanner (3DHISTECH, Hungary).

2.6 | Immunofluorescence staining

Frozen liver tissue sections were blocked with 10% bovine serum albumin (BSA) at room temperature for 1 hour. Anti-PLK1 (1:200; Abcam, USA) and anti-α-SMA (1:200; Abcam, USA) antibodies were added to the sections and incubated at 4°C for 16 hour. Sections were then incubated with a combination of TRITC-conjugated (1:100, ZSGB-Bio, China) and FITC-conjugated (1:100, ZSGB-Bio, China) secondary antibodies at room temperature for 60 mins in the dark. The positive expression of α-SMA and PLK1 was observed by inversion fluorescence microscopy.
2.7 | Serum biochemical value analysis

Serum was collected from whole blood samples by centrifugation at 1000 g for 30 minutes at room temperature. Serum alanine aminotransferase and aspartate aminotransferase (ALT and AST) were measured using an ALT and AST Assay Kit (Jiancheng Bioengineering Institute, Nanjing, China) according to the manufacturer's instructions.

2.8 | Western blot analysis

Proteins samples were extracted from primary HSCs and LX-2 cells using RIPA lysis buffer (Beyotime, China). Equal amounts of proteins were separated by 10% SDS-PAGE and transferred onto PVDF membranes (Millipore, USA). The membranes were blocked with 5% skim milk for 1 hour at room temperature and then incubated with primary antibodies overnight at 4°C. The following antibodies were used for Western blotting: β-actin (1:500; Bioss, China), Col1α1 (1:500; Bioss), α-SMA (1:500; Bioss), PLK1 (1:1000; Abcam), Bax (1:800; Abcam), Bcl-2 (1:800; Abcam), cleaved caspase-3 (1:1000; Abcam), β-catenin (1:500, Bioss), c-Myc (1:500; Bioss) and Cyclin D1 (1:500; Bioss). The membranes were incubated with HRP-conjugated secondary antibodies (1:10000; ZSGB-Bio, China) for 60 minutes at room temperature. The protein bands were detected with a chemiluminescent (ECL) system (Bio-Rad, USA) and analysed using IMAGE J software (National Institutes of Health, USA).

2.9 | Real-time PCR analysis

Total RNA was extracted from primary HSCs or LX-2 cells using the TRIzol reagent (Invitrogen, USA) following the manufacturer’s protocols. Quantitative detection was performed using a Spectrophotometer NanoDrop 2000 (Thermo Scientific, USA), and cDNA was synthesized using a PrimeScript™RT Master Mix (Takara, Japan). Real-time PCR samples were run on the CFX96 Real-Time PCR Detection System (Bio-Rad, USA) for 10 minutes at 95°C, followed by 40 cycles at 95°C for 15 seconds and at 60°C for 1 minute. GAPDH expression was used as an internal control. The sequences of the primers for real-time PCR are listed in Table 1.

2.10 | Cell culture

LX-2 cells were cultured in DMEM (Gibco, USA) supplemented with 10% foetal bovine serum (Gibco, USA), 100 U/mL penicillin and 100 mg/mL streptomycin, and incubated in a 5% CO₂ incubator at 37°C.

2.11 | Transfection with PLK1 plasmid in vitro

To overexpress PLK1, LX-2 cells were transiently transfected with pLenO-GFP-3XFLAG-PLK1 (Ruan Tuo, China) using Lipofectamine™ 2000 (Invitrogen, USA) according to the manufacturer’s guidelines. LX-2 cells were treated with an empty plasmid as a negative control. The transfection efficiency was measured by Western blotting and real-time PCR analysis.

2.12 | Transfection with PLK1 CRISPR/Cas9 lentivirus in vitro

A validated human PLK1 CRISPR/Cas9 KO lentivirus was purchased from Hanheng Biotechnology (Shanghai, China). The PLK1-specific gRNA sequence was 5’-CACCCTGCCAAAGCGGCTCTAGGATCT-3’. Briefly, LX-2 cells were transfected to 12-well plates. After 24 hours, the cells had reached 60%-70% confluency and were transfected with PLK1 CRISPR/Cas9 lentivirus according to the manufacturer's protocol. The transfection efficiency was measured by Western blotting and real-time PCR analysis.

| Gene   | Forward(5’-3’) | Reverse(5’-3’) |
|--------|---------------|---------------|
| Mouse  |               |               |
| PLK1   | CTCCCTTTGAGACCTCGTGC | TGGGATGTTGAGCCAGGTAA |
| α-SMA  | CGGGAGAAAATGACCCAGATT | AGGGACAGCAACCAGCTGAATAG |
| Col1α1 | GGAAGATCTGATGAGACCGCTAAC | ACACAGGCTGAGCTCAGTCAT |
| TIMP-1 | GCAACTGCTGGACCTGTCATAA | CCGCCCCTGATGAGAAAAC |
| GAPDH  | GGACCTCATGGCCCTCATACAGG | TAGGGCCCTCTTCTGGTCAGT |
| Human  |               |               |
| PLK1   | CCACTCACCTGCTGACCATT | CTTACCTGTCTTCTGACACC |
| α-SMA  | ATCAAGGAGAGAACTGTTATGGAATAG | GATGAAAGGATGCTGGAAAGGGT |
| Col1α1 | TCAAGGACCATGTTTGGACAGG | TCTGGGTAGGATGTGGTC |
| TIMP-1 | CTTCTCAATCTGAGGAATTCT | ACACTGTGAATGATCAGT |
| β-actin| GCCAACACAGTGTGCTGTCG | CTCAAGGAGCAATGTGTCAGT |

**TABLE 1** Primers sequences used for real-time PCR
2.13 | Cell proliferation assay

The proliferation of LX-2 cells was determined by a Cell Counting Kit-8 (CCK-8) (Best Bio, China). Briefly, the transfected cell suspensions were collected, added to 96-well plates and incubated at 37°C overnight. Then, 10 µL of the CCK-8 solution was added to each well for 3 hours, and the absorbance value in each well at 450 nm was detected using a microplate reader (Bio-Tek EL, USA).

2.14 | Cell apoptosis analysis

The apoptosis of LX-2 cells was analysed by flow cytometry using the Annexin V-FITC/PI Apoptosis Kit (Best Bio, China). Cells were centrifuged and suspended in 400 µL Annexin binding solution. Then, 5 µL Annexin V-FITC staining solution was added to the suspension and incubated for 15 minutes followed by the addition of PI and incubated for 5 minutes in the dark at 4°C before flow cytometry analysis (Beckman Coulter, USA).

2.15 | Cell cycle analysis

The amount of DNA present in LX-2 cells was assessed by the Cell Cycle Analysis Kit (Best Bio, China). The cells were collected by centrifugation, fixed with cold ethanol overnight at 4°C, and then centrifuged and washed. The cells were suspended in 500 µL cold PBS with 20 µL RNase A solution at 37°C for 30 minutes. After filtration using a 400-mesh screen, the cells were resuspended in 400 µL PI and incubated at 4°C in the dark for 30 minutes. Finally, the cells were analysed by flow cytometry (Beckman Coulter, USA).

2.16 | Statistical analysis

Data collected from this study were analysed using one-way analysis of variance (ANOVA), followed by Newman-Keuls post hoc test (Prism 5.0 GraphPad software, USA), and are expressed as the mean ± SEM.
3 | RESULTS

3.1 | PLK1 was highly expressed in human liver fibrosis tissues

We analysed PLK1 levels in human healthy control and liver fibrosis tissue. The pathological results showed that the liver tissues were structurally disordered and the fibrosis tissues were significantly hyperplastic, as shown by H&E staining in patients with liver fibrosis (Figure 1A). The fibrotic parts were indicated by Sirius red staining (Figure 1A), and activated HSCs were identified by α-SMA-positive areas (Figure 1B). Immunohistochemical analyses revealed low expression of PLK1 in healthy livers, whereas much higher expression of PLK1 was evident in the perivascular region by Western blotting (Figure 1C). Similarly, the mRNA levels of PLK1 and fibrogenic genes (α-SMA, Col1α1 and TIMP-1) were higher in liver fibrosis than in healthy livers, as shown by real-time PCR (Figure 1D). These results indicate that the expression of PLK1 is elevated in liver fibrosis, and that up-regulated PLK1 expression is associated with liver fibrosis.

3.2 | Up-regulation of PLK1 expression in HSCs is associated with CCl4-induced liver fibrosis

To evaluate whether PLK1 expression is correlated with liver fibrosis, we developed a CCl4-induced mouse liver fibrosis model for histopathological studies. Liver injury was observed in liver fibrosis mice by H&E staining (Figure S1A). The collagen area was indicated by Sirius red staining, and the activated HSCs were highlighted by α-SMA positivity (Figure S1A). Immunohistochemical analyses demonstrated that PLK1 expression was increased in CCl4-induced mice compared with vehicle mice (Figure S1A). The α-SMA-positive and PLK1-positive area quantitative results are shown in Figure S1A. Serum levels of AST and ALT were higher in CCl4-induced liver fibrosis mice compared with vehicle mice (Figure S1B). Furthermore, we found an increase in PLK1, α-SMA and Col1α1 mRNA and protein levels in primary HSCs isolated from CCl4-induced liver fibrosis mice compared with vehicle mice (Figure S1B). We performed co-localization studies of PLK1 with α-SMA by immunofluorescence double staining in vivo. Interestingly, the results revealed a dramatic up-regulation of PLK1 (red) expression in the activated HSCs that were positive for α-SMA (green) after the induction of liver fibrosis by CCl4 (Figure S1E). The co-localization positive area quantitative results are shown in Figure S1E. These studies demonstrate that PLK1 expression is increased in the liver fibrosis mouse model, which is consistent with the results in humans, suggesting that PLK1 may be related to HSCs activation in liver fibrosis.

3.3 | Inhibition of PLK1 alleviates CCl4-induced liver fibrosis

To define the role of PLK1 in liver fibrogenesis, we investigated the functional effects of PLK1 on liver fibrosis in CCl4-induced liver fibrosis mice in vivo. Mice were injected with adeno-associated virus (AAV)-shRNA-PLK1 to knockdown PLK1 expression in the liver, and mice injected with an empty AAV vector were used as controls (Figure 2A). Mice were repetitively treated with CCl4 for 6 weeks. We detected the knockdown efficiency of AAV-shPLK1 on PLK1 by Western blotting and real-time PCR (Figure 2B). Inhibition of PLK1 alleviated CCl4-induced liver injury and fibrosis compared with AAV-empty–treated mice by H&E and Sirius red staining (Figure 2C). Consistently, IHC staining results showed that the decrease in PLK1 significantly reduced α-SMA expression (Figure 2C). The quantification of α-SMA-positive and PLK1-positive areas is shown in Figure 2C. Furthermore, there was a common reduction in the levels of ALT and AST in serum from CCl4-induced liver fibrosis mice injected with AAV-shPLK1 compared with the mice that received AAV-empty (Figure 2D). Moreover, low expression of PLK1 by AAV-shPLK1 led to a significant decrease in the expression of α-SMA and Col1α1 protein in HSCs from CCl4-induced liver fibrosis mice (Figure 2E). The mRNA levels of α-SMA, Col1α1 and TIMP-1 were notably attenuated in CCl4-treated PLK1 knockdown mice compared with AAV-empty mice (Figure 2F). Collectively, these observations revealed that inhibition of PLK1 alleviates liver fibrosis and the activation of HSCs in vivo.

3.4 | Blocking PLK1 attenuates the activation of LX-2 cells stimulated with TGF-β1

To further assess whether PLK1 expression is related to HSCs activation in liver fibrosis, we investigated the functional effects of silencing PLK1 on liver fibrosis in LX-2 cells in vitro. We found that α-SMA and PLK1 expression levels were enhanced in a time-dependent manner by Western blotting in LX-2 cells stimulated with TGF-β1 (Figure 3A). Therefore LX-2 cells were treated with 10 ng/mL TGF-β1 for 48 hour in the following experiments. Protein expression and mRNA levels of PLK1, α-SMA and Col1α1 were enhanced compared with the controls by Western blotting and real-time PCR (Figure 3B,C). PLK1 expression was also increased in LX-2 cells stimulated with TGF-β1 (10 ng/mL), as determined by immunofluorescence staining (Figure 3D). We used clustered regularly interspaced short palindromic repeat (CRISPR)-CRISPR-associated protein 9 (CRISPR/Cas9) to silence PLK1 by co-expressing PLK1-specific RNA and Cas9 endonuclease. The green fluorescent protein (GFP) signal in the LX-2 cells transfected with Cas9-grRNA-PLK1 lentivirus showed that the cells were successfully infected (Figure 3E). After the transfection of Cas9-grRNA-PLK1 into LX-2 cells, the efficiency of PLK1
silencing was measured and confirmed by Western blotting and real-time PCR (Figure 3F). Inhibition of PLK1 significantly reduced the viability of LX-2 cells stimulated with TGF-β1 by CCK-8 analysis (Figure 4A). After the transfection of Cas9-gRNA-PLK1 into LX-2 cells, protein expression of α-SMA and Col1α1 was remarkably down-regulated compared with that of the Cas9-empty group (Figure 4B). Consistently, treatment of LX-2 cells with Cas9-gRNA-PLK1 significantly reduced the mRNA levels of α-SMA, Col1α1 and TIMP-1 compared with the Cas9-empty group (Figure 4C). These results indicated that PLK1 was enhanced in LX-2 cells stimulated with TGF-β1 and that blocking PLK1 attenuated the activation of these TGF-β1-treated LX-2 cells.

### 3.5 PLK1 promotes the activation of LX-2 cells stimulated with TGF-β1

Next, LX-2 cells were transfected with GTP-PLK1 plasmid, and the efficiency of PLK1 overexpression was measured by Western blotting (Figure S2A). PLK1 overexpression significantly increased LX-2 cell viability by CCK-8 analysis compared with the GTP-empty plasmid-transfected group (Figure S2B). We identified that the expression levels of α-SMA, Col1α1 and TIMP-1 were remarkably up-regulated in LX-2 cells following overexpression of the GTP-PLK1 plasmid compared with the GTP-empty group (Figure S2C). Similarly, PLK1 overexpression markedly increased the mRNA levels of α-SMA, Col1α1 and TIMP-1.
and TIMP-1 compared with the GTP-empty plasmid-transfected group (Figure S2D). These results indicate that PLK1 promotes the activation of LX-2 cells stimulated by TGF-β1 in vitro.

### 3.6 Inhibition of PLK1 facilitates apoptosis of HSCs in liver fibrosis

To verify the effect of PLK1 knockdown on the apoptosis of HSCs, we detected the expression of cleaved caspase-3, α-SMA and Bax by Western blot analysis. The results showed that the expression of cleaved caspase-3 was increased and that the Bax/α-SMA ratio was enhanced in HSCs from CCl₄-induced liver fibrosis mice injected with AAV-shPLK1 compared with the AAV-empty group (Figure 5A). Consistently, the expression of cleaved caspase-3 and the Bax/α-SMA ratio was increased compared with the Cas9-empty group after the transfection of LX-2 cells with Cas9-gRNA-PLK1 (Figure 5B). In contrast, we identified that the expression of cleaved caspase-3 and the Bax/α-SMA ratio were significantly down-regulated in LX-2 cells following GTP-PLK1 overexpression compared with the GTP-empty group (Figure 5C). We further investigated the effect of PLK1 on the cell cycle of LX-2 cells by flow cytometry. Inhibition of PLK1 induced cell cycle arrest in G0/G1 in LX-2 cells stimulated with TGF-β1 (Figure 6D). In contrast, PLK1 overexpression advanced LX-2 cells into G2/M compared with the GTP-empty group by flow cytometry analysis (Figure 6E). Additionally, we used a TGF-β1 inhibitor to block TGF-β1 signalling. As shown in Figure S3A,B, the expression of PLK1 was significantly decreased in LX-2 cells treated with TGF-β1 inhibitor. These results indicate that PLK1 promoted the proliferation of HSCs by regulating the Wnt/β-catenin signalling pathway in liver fibrosis in vivo and in vitro (Figure 7).
Liver fibrosis is an important global concern, and there is currently no approved treatment. It is a reversible pathological process in which an imbalance between the synthesis and degradation of the ECM leads to abnormal deposition of fibrous connective tissue in the liver. The activation, proliferation and transformation of HSCs caused by liver injury are important factors in the process of liver fibrosis. However, the molecular mechanisms by which HSCs are activated to induce fibrosis have not been fully elucidated. In our study, we found that increased PLK1 expression was associated with liver fibrosis and generated reliable data to support the pro-fibrosis effect of PLK1. We demonstrated that PLK1 was increased in human liver fibrosis samples and primary HSCs from CCl4-induced fibrosis mice using Western blot and real-time PCR, whereas immunofluorescence and IHC assays further showed PLK1 was up-regulated in the cytoplasm. In addition, we demonstrated that the up-regulation of PLK1 in HSCs induced the expression of α-SMA, Col1α1 and TIMP-1 and promoted the activation of HSCs. We also found that the induction of PLK1 expression in HSCs further promoted the proliferation and activation of HSCs by increasing the expression of specific transcription factors associated with the Wnt/β-catenin signalling pathway. In CCl4-induced liver fibrosis mice, we found that reduced expression of PLK1 by AAV-shPLK1 significantly decreased liver fibrosis. Our results suggest that PLK1 may be a potential therapeutic target for liver fibrosis.

PLK1 is a highly conserved serine/threonine kinase. Recent studies have revealed that PLK1 has a broad regulatory role in cell mitosis and plays a critical role in cell proliferation. It has been confirmed that PLK1 is overexpressed in many different tumour types and thus has a critical effect on tumour development. We found that inhibition of PLK1 expression could reduce the activation of HSCs and thus alleviate liver fibrosis. Moreover, inhibition of PLK1 could reduce the activation of the Wnt/β-catenin signalling pathway in vivo and down-regulate the expression of β-catenin, c-Myc and Cyclin D1 to block the proliferation of HSCs. Similarly, low expression of PLK1 by Cas9-gRNA-PLK1 lentivirus down-regulated the expression of cell cycle-related proteins in TGF-β1-stimulated LX-2 cells in vitro. In contrast, PLK1 overexpression by GTP-PLK1 plasmid increased the expression of cell cycle-related proteins β-catenin, c-Myc and Cyclin D1 in TGF-β1-stimulated LX-2 cells in vitro. Interestingly, inhibition of TGF-β1...
**FIGURE 6** PLK1 promotes the proliferation of HSCs in liver fibrosis. A, β-catenin, c-Myc and Cyclin D1 expression in primary HSCs isolated from mice injected with AAV-shPLK1 virus by Western blotting. *P < 0.05, **P < 0.01 vs saline; †P < 0.05, ‡P < 0.01 vs CCl4 + AAV-empty. (B,C) β-catenin, c-Myc and Cyclin D1 expression was assessed in LX-2 cells transfected with Cas9-gRNA-PLK1 or GTP-PLK1. *P < 0.05, **P < 0.01 vs control; †P < 0.05, ‡P < 0.01 vs TGF-β1 + Cas9-empty; &P < 0.05, &&P < 0.01 vs TGF-β1 + GTP-empty. D, Flow cytometry analysis was performed to examine the cell cycle distribution of TGF-β1–activated LX-2 cells transfected with Cas9-gRNA-PLK1. E, Effect of up-regulated PLK1 on the cell cycle of TGF-β1–activated LX-2 cells transfected with GTP-PLK1 by flow cytometry analysis. Representative images of at least three independent experiments. Data shown are the mean ± SEM.

**FIGURE 7** PLK1 regulates hepatic stellate cell activation and liver fibrosis through Wnt/β-catenin signalling pathway
signalling decreased PLK1 expression, suggesting that a PLK1-mediated Wnt/β-catenin signalling axis plays an important role in the process of liver fibrosis by enhancing the activation of HSCs by TGF-β1. Additionally, we observed that inhibition of PLK1 expression significantly increased HSCs apoptosis. We identified that PLK1 inhibition activated apoptotic executive proteins caspase-3 and increased the Bax/Bcl-2 ratio to promote the apoptosis of HSCs. Similarly, knockdown of PLK1 by Cas9-gRNA-PLK1 lentivirus up-regulated the expression of apoptosis-related proteins and increased the Bax/Bcl-2 ratio in LX-2 cells. In addition, PLK1 overexpression by PLK1-GTP plasmid decreased the expression of cleaved caspase-3 and the Bax/Bcl-2 ratio in TGF-β1-stimulated LX-2 cells in vitro. Furthermore, the results of flow cytometry showed that inhibition of PLK1 expression increased the number of apoptotic LX-2 cells. Considering this combined effect, PLK1 promoted the activation and proliferation of HSCs and inhibited apoptosis in liver fibrosis.

We conclude that PLK1 is an important molecule for HSCs activation in liver fibrosis. We identified low expression of PLK1 in liver fibrosis. Down-regulated PLK1 in HSCs further alleviated the expression of proteins associated with HSCs proliferation (c-Myc and Cyclin D1) and enhanced the expression of apoptosis-related proteins (cleaved caspase-3 and Bax/Bcl-2). The current study demonstrates that inhibition of PLK1 expression prevents HSCs activation and proliferation to reduce liver fibrosis through the Wnt/β-catenin signalling pathway. Our present study suggests that PLK1 is an attractive novel therapeutic target for liver fibrosis.

ACKNOWLEDGEMENTS
This work was supported by the National Science Foundation of China (Nos. 81770609).

CONFLICT OF INTEREST
The authors declare no conflict of interest.

AUTHOR CONTRIBUTIONS
YC and XC conceived and designed the study, YC, XC and SZ performed the experiments. FTB collected and coordinated the data. YRJ provided the mouse. XSD and YC wrote the manuscript. XMM, formed the experiments. FTB collected and coordinated the data. The authors declare no conflict of interest.

REFERENCES
1. Liu J, Zhao G, AI B, et al. Effects of siniruangan recipe on proliferation, apoptosis and activation of human hepatic stellate cell line LX-2. Pharmacology. 2019;104(5-6):342-351.
2. Xu M, Xu HH, Lin Y, et al. LECT2, a ligand for Tie1, plays a crucial role in liver fibrogenesis. Cell. 2019;178(6):1478-1492.e20.
3. Qu C, Zheng D, Li S, et al. Tyrosine kinase SYK is a potential therapeutic target for liver fibrosis. Hepatology. 2018;68(3):1125-1139.
4. Nakano Y, Kamiya A, Sumiyoshi H, Tsuruya K, Kagawa T, Inagaki Y. A novel deactivation factor of fibrogenic hepatic stellate cells induces regression of liver fibrosis in mice. Hepatology. 2020;63(1):79-87.
5. Pradhan-Sundd T, Kosar K, Saggi H, et al. Wnt/beta-Catenin signalling plays a protective role in the Mdr2 KO murine model of cholestatic liver disease. Hepatology. 2020;71(5):1732-1749.
6. Lv J, Bai R, Wang L, Gao J, Zhang H. Artesunate may inhibit liver fibrosis via the FAK/Akt/beta-catenin pathway in LX-2 cells. BMC Pharmacol Toxicol. 2018;19:64.
7. Bu FT, Chen Y, YuHX, et al. SENP2 alleviates CCl4-induced liver fibrosis by promoting activated hepatic stellate cell apoptosis and reversion. Toxicol Lett. 2018;289:86-98.
8. Yu HK, Yao Y, Bu FT, et al. Blockade of YAP alleviates hepatic fibrosis through accelerating apoptosis and reversion of activated hepatic stellate cells. Mol Immunol. 2019;107:29-40.
9. Gao Z, Man X, Li Z, et al. PLK1 promotes proliferation and suppresses apoptosis of renal cell carcinoma cells by phosphorylating MCM3. Cancer Gene Ther. 2019.
10. Shin SB, Jang HR, Xu R, Won JY, Yim H. Active PLK1-driven metastasis is amplified by TGF-beta signalling that forms a positive feedback loop in non-small cell lung cancer. Oncogene. 2019;39(4):767-785.
11. Studach LL, Rakotomalala L, Wang WH, et al. Polo-like kinase 1 inhibition suppresses hepatitis B virus X protein-induced transformation in an in vitro model of liver cancer progression. Hepatology. 2009;50:414-423.
12. Reda M, Ngamcherdtrakul W, Gu S, et al. PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer. Cancer Lett. 2019;467:9-18.
13. Song R, Hou G, Yang J, et al. Effects of PLK1 on proliferation, invasion and metastasis of gastric cancer cells through epithelial-mesenchymal transition. Oncol Lett. 2018;16:5739-5744.
14. Lian G, Li L, Shi Y, et al. BI2536, a potent and selective inhibitor of polo-like kinase 1, shows promising therapeutic effects on gastric cancer cells. Int J Oncol. 2018;52:804-814.
15. Li HY, Luo F, Li XY, et al. Inhibition of polo-like kinase 1 by BI2536 decreases the multidrug resistance of human hepatoma cells in vitro and in vivo. Anticancer Agents Med Chem. 2019;19:740-749.
16. Min F, Gao F, Liu Z. Screening and further analyzing differentially expressed genes in acute idiopathic pulmonary fibrosis with DNA microarray. Eur Rev Med Pharmacol Sci. 2013;17:2784-2790.
17. Cristobal I, Rojo F, Madoz-Gurpide J, Garcia-Foncillas J. Cross talk between Wnt/beta-catenin and CIP2A/Plk1 signalling in prostate cancer: promising therapeutic implications. Mol Cell Biol. 2016;36:1734-1739.
18. Li J, Karki A, Hodges KB, et al. Cotargeting polo-like kinase 1 and the Wnt/beta-catenin signaling pathway in castration-resistant prostate cancer. Mol Cell Biol. 2015;35:4185-4198.
19. Wang X, Tang X, Gong X, Albanis E, Friedman SL, Mao Z. Regulation of hepatic stellate cell activation and growth by transcription factor myocyte enhancer factor 2. Gastroenterology. 2004;127:1174-1188.
20. Friedman SL, Roll FJ. Isolation and culture of hepatic lipocytes, Kupffer cells, and sinusoidal endothelial cells by density gradient centrifugation with Stractan. Anal Biochem. 1987;161:207-218.
21. Lan HY, Hutchinson P, Tesch GH, Mu W, Atkins RC. A novel method of microwave treatment for detection of cytoplasmic and nuclear antigens by flow cytometry. J Immunol Methods. 1996;190:1-10.
22. Pinheiro D, Dias I, Ribeiro Silva K, et al. Mechanisms underlying cell therapy in liver fibrosis. An overview. Cells. 2019;8(11):1339.
cells via STAT3-p53 pathway to attenuate liver fibrosis. Cell Signal. 2020;66:109445.

24. Yan J, Huang H, Liu Z, et al. Hedgehog signaling pathway regulates hexavalent chromium-induced liver fibrosis by activation of hepatic stellate cells. Toxicol Lett. 2020;320:1-8.

25. de Oliveira da Silva B, Ramos LF, Moraes KCM. Molecular interplays in hepatic stellate cells: apoptosis, senescence, and phenotype reversion as cellular connections that modulate liver fibrosis. Cell Biol Int. 2017;41:946-959.

26. Mai J, Zhong ZY, Guo GF, et al. Polo-Like Kinase 1 phosphorylates and stabilizes KLF4 to promote tumorigenesis in nasopharyngeal carcinoma. Theranostics. 2019;9:3541-3554.

27. Yim MS, Soung NK, Han EH, et al. Vitamin E-conjugated phosphopeptide inhibitor of the polo-box domain of polo-like kinase 1. Mol Pharm. 2019;16(12). https://doi.org/10.1021/acs.molpharmaceut.9b00757

28. De Blasio C, Zonfrilli A, Franchitto M, et al. PLK1 targets NOTCH1 during DNA damage and mitotic progression. J Biol Chem. 2019;294:17941-17950.

29. Goan YG, Liu PF, Chang HW, et al. Kinome-wide screening with small interfering RNA identified Polo-like Kinase 1 as a key regulator of proliferation in oral cancer cells. Cancers (Basel). 2019;11(8):1117.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Chen Y, Chen X, Ji Y-R, et al. PLK1 regulates hepatic stellate cell activation and liver fibrosis through Wnt/β-catenin signalling pathway. J Cell Mol Med. 2020;24:7405-7416. https://doi.org/10.1111/jcmm.15356